tert-butyl 3-(propylamino)propanoate | 701300-49-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl 3-(propylamino)propanoate
• 英文别名: t-butyl 3-N-n-propylaminopropionate
• CAS: 701300-49-4
• 化学式: C₁₀H₂₁NO₂
• 分子量: 187.282
• InChiKey: VQGUHQKNRANHRQ-UHFFFAOYSA-N

物化性质

• 沸点：
  81-82 °C(Press: 10 Torr)
• 密度：
  0.909±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-(propylamino)propanoate 在 三氯异氰尿酸 作用下， 以 乙酸乙酯 为溶剂， 反应 1.0h， 以99%的产率得到t-butyl N-chloro-3-propyloaminopropionate
  参考文献：
  名称：

  bN-氯乙氨基碳负离子的分子内反应合成取代的氮丙啶

  摘要：

  通过在1-N-氯-2-烷氧基羰基（氰基、苯磺酰基）乙胺中进行氯化物的分子内亲核取代，阐述了一种简单、有效的合成2-烷氧基羰基、2-氰基、2-苯磺酰基N-烷基氮丙啶的方法。这些取代的 N-氯胺很容易通过伯胺加合物与迈克尔受体的 N-氯化作用而擦除。

  DOI：

  10.3987/com-08-s(n)115
• 作为产物：
  描述：

  正丙胺 、 丙烯酸叔丁酯 以 乙醇 为溶剂， 以78%的产率得到tert-butyl 3-(propylamino)propanoate
  参考文献：
  名称：

  bN-氯乙氨基碳负离子的分子内反应合成取代的氮丙啶

  摘要：

  通过在1-N-氯-2-烷氧基羰基（氰基、苯磺酰基）乙胺中进行氯化物的分子内亲核取代，阐述了一种简单、有效的合成2-烷氧基羰基、2-氰基、2-苯磺酰基N-烷基氮丙啶的方法。这些取代的 N-氯胺很容易通过伯胺加合物与迈克尔受体的 N-氯化作用而擦除。

  DOI：

  10.3987/com-08-s(n)115

文献信息

• DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS
  申请人：Molteni Valentina

  公开号：US20090012094A1

  公开（公告）日：2009-01-08

  Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

  本文介绍了一种包含二芳胺结构特征的化合物。还介绍了制备这种化合物的方法，使用这种化合物调节c-kit受体活性的方法，以及包含这种化合物的制药组合物和药物。本文还介绍了使用这种化合物、制药组合物和药物治疗和/或预防和/或抑制和/或改善与c-kit受体活性相关的病理学和/或症状学疾病或状况的方法。
• Imidazole derivative, process for producing the same, and use
  申请人：Kubo Keiji

  公开号：US20070004736A1

  公开（公告）日：2007-01-04

  There is provided an imidazole derivative useful as a thrombosis treating agent, which is represented by the formula (I): wherein R represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent linear hydrocarbon group, X represents an optionally substituted divalent hydrocarbon group, Y represents —CO—, —S(O)—, —S(O) 2 — or a bond, ring A represents an optionally substituted pyrrolidine ring, an optionally substituted piperidine ring or an optionally substituted perhydroazepine ring, Z 1 and Z 3 independently represent a bond or an optionally substituted divalent linear hydrocarbon group, Z 2 represents —N(R 1 )—, —O—, —S(O)—, —S(O) 2 —, —CO—, —CH(R 1 )— or a bond, ring B represents an optionally substituted imidazole ring, wherein a substituent which the optionally substituted imidazole ring represented by ring B may have may be taken together with R 1 to form an optionally substituted ring, and a represents 0, 1 or 2.

  提供了一种咪唑衍生物，用作治疗血栓的药物，其化学式表示为(I)式：其中R代表可选取代的环烃基或可选取代的杂环基，W代表键或可选取代的二价直链烃基，X代表可选取代的二价烃基，Y代表-CO-、-S(O)-、-S(O)2-或键，环A代表可选取代的吡咯烷环、可选取代的哌啶环或可选取代的过氢杂环己烷环，Z1和Z3独立地代表键或可选取代的二价直链烃基，Z2代表-N(R1)-、-O-、-S(O)-、-S(O)2-、-CO-、-CH(R1)-或键，环B代表可选取代的咪唑环，其中可选取代的咪唑环所具有的取代基可以与R1一起形成可选取代的环，a代表0、1或2。
• Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors
  申请人：Molteni Valentina

  公开号：US20070149538A1

  公开（公告）日：2007-06-28

  Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

  本文描述了包含二芳胺结构特征的化合物。还描述了制备这种化合物的方法，使用这种化合物调节c-kit受体活性的方法，以及包含这种化合物的药物组合物和药物。本文还描述了使用这种化合物、药物组合物和药物治疗和/或预防和/或抑制和/或改善与c-kit受体活性相关的病理学和/或症状学疾病或状况的方法。
• 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS
  申请人：Chianelli Donatella

  公开号：US20110053952A1

  公开（公告）日：2011-03-03

  The invention provides compounds of Formula (I) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, Fms, KDR, c-raf or b-raf kinases.

  本发明提供了式(I)的化合物及其制药组合物，它们可用作蛋白激酶抑制剂，以及使用这些化合物治疗、改善或预防与异常或失调的激酶活性相关的疾病或症状的方法。在某些实施例中，本发明提供使用这些化合物治疗、改善或预防涉及c-kit、PDGFRα、PDGFRβ、CSF1R、Abl、BCR-Abl、CSK、JNK1、JNK2、p38、p70S6K、TGFβ、SRC、EGFR、trkB、FGFR3、Fes、Lck、Syk、RAF、MKK4、MKK6、SAPK2β、BRK、Fms、KDR、c-raf或b-raf激酶异常活化的疾病或症状的方法。
• IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE
  申请人：KUBO Keiji

  公开号：US20110009389A1

  公开（公告）日：2011-01-13

  There is provided an imidazole derivative useful as a thrombosis treating agent, which is represented by the formula (I): wherein R represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent linear hydrocarbon group, X represents an optionally substituted divalent hydrocarbon group, Y represents —CO—, —S(O)—, —S(O) 2 — or a bond, ring A represents an optionally substituted pyrrolidine ring, an optionally substituted piperidine ring or an optionally substituted perhydroazepine ring, Z 1 and Z 3 independently represent a bond or an optionally substituted divalent linear hydrocarbon group, Z 2 represents —N(R 1 )—, —O—, —S(O)—, —S(O) 2 —, —CO—, —CH(R 1 )— or a bond, ring B represents an optionally substituted imidazole ring, wherein a substituent which the optionally substituted imidazole ring represented by ring B may have may be taken together with R 1 to form an optionally substituted ring, and a represents 0, 1 or 2.

  提供了一种咪唑衍生物，可用作治疗血栓的药物，其化学式表示为（I）：其中R代表可选取代的环烃基或可选取代的杂环基，W代表键或可选取代的二价线性烃基，X代表可选取代的二价烃基，Y代表-CO-，-S（O）-，-S（O）2-或键，环A代表可选取代的吡咯烷环，可选取代的哌啶环或可选取代的过氢化脂肪环，Z1和Z3独立地代表键或可选取代的二价线性烃基，Z2代表-N（R1）-，-O-，-S（O）-，-S（O）2-，-CO-，-CH（R1）-或键，环B代表可选取代的咪唑环，其中可选取代的咪唑环所代表的取代基可以与R1一起形成可选取代的环，a代表0，1或2。